Virios Therapeutics (VIRI) Competitors $5.96 -0.09 (-1.49%) As of 03/26/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. KROS, TRML, ALT, ZVRA, DNA, ORKA, PRTC, SLDB, GLUE, and ERASShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Keros Therapeutics (KROS), Tourmaline Bio (TRML), Altimmune (ALT), Zevra Therapeutics (ZVRA), Ginkgo Bioworks (DNA), Oruka Therapeutics (ORKA), PureTech Health (PRTC), Solid Biosciences (SLDB), Monte Rosa Therapeutics (GLUE), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Keros Therapeutics Tourmaline Bio Altimmune Zevra Therapeutics Ginkgo Bioworks Oruka Therapeutics PureTech Health Solid Biosciences Monte Rosa Therapeutics Erasca Keros Therapeutics (NASDAQ:KROS) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations. Which has more risk & volatility, KROS or VIRI? Keros Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Which has higher earnings and valuation, KROS or VIRI? Virios Therapeutics has lower revenue, but higher earnings than Keros Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M125.57-$152.99M-$5.01-2.19Virios TherapeuticsN/AN/A-$5.30M-$0.27-22.07 Does the MarketBeat Community favor KROS or VIRI? Keros Therapeutics received 60 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 70.00% of users gave Keros Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformKeros TherapeuticsOutperform Votes6370.00% Underperform Votes2730.00% Virios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Does the media refer more to KROS or VIRI? In the previous week, Keros Therapeutics had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Keros Therapeutics and 1 mentions for Virios Therapeutics. Keros Therapeutics' average media sentiment score of 1.57 beat Virios Therapeutics' score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Virios Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is KROS or VIRI more profitable? Virios Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -27,890.94%. Keros Therapeutics' return on equity of -41.74% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics-27,890.94% -41.74% -38.42% Virios Therapeutics N/A -130.33%-115.00% Do analysts recommend KROS or VIRI? Keros Therapeutics currently has a consensus price target of $42.33, indicating a potential upside of 285.20%. Virios Therapeutics has a consensus price target of $3.00, indicating a potential downside of 49.66%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Keros Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.57Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in KROS or VIRI? 71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryKeros Therapeutics beats Virios Therapeutics on 13 of the 17 factors compared between the two stocks. Remove Ads Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.78M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-22.077.2023.1319.03Price / SalesN/A226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book29.806.476.944.33Net Income-$5.30M$141.90M$3.20B$247.06M7 Day Performance-12.74%-3.20%-2.33%-0.37%1 Month Performance26.54%-5.64%2.84%-3.85%1 Year Performance1,144.00%-7.47%10.75%1.27% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios Therapeutics0.4091 of 5 stars$5.96-1.5%$3.00-49.7%+1,132.2%$114.78MN/A-22.075News CoverageKROSKeros Therapeutics3.8017 of 5 stars$11.62+0.3%$42.33+264.3%-83.0%$471.33M$3.55M-2.23100Positive NewsTRMLTourmaline Bio1.9928 of 5 stars$18.26-2.9%$53.14+191.0%-26.9%$468.24MN/A-6.4844Positive NewsHigh Trading VolumeALTAltimmune2.7087 of 5 stars$5.97+0.8%$20.83+249.0%-37.3%$459.77M$20,000.00-3.8550ZVRAZevra Therapeutics3.0403 of 5 stars$8.35+0.5%$22.14+165.2%+34.0%$451.87M$23.61M-4.2420DNAGinkgo Bioworks0.6567 of 5 stars$7.79+11.7%$4.58-41.2%N/A$451.80M$227.04M-0.601,218ORKAOruka Therapeutics3.211 of 5 stars$11.89+7.2%$39.86+235.2%N/A$445.17MN/A-1.90N/APositive NewsPRTCPureTech Health1.5493 of 5 stars$17.99+3.1%$45.00+150.2%-34.6%$430.65M$3.33M0.00100Gap DownSLDBSolid Biosciences3.4274 of 5 stars$5.36+5.3%$15.67+192.3%-69.3%$415.36M$8.09M-1.76100Positive NewsGLUEMonte Rosa Therapeutics2.9993 of 5 stars$6.73+7.3%$15.25+126.6%-25.3%$413.47M$14.98M-3.6890Short Interest ↓ERASErasca3.6638 of 5 stars$1.46+1.4%$4.90+235.6%-24.8%$412.78MN/A-1.76120Analyst ForecastNews Coverage Remove Ads Related Companies and Tools Related Companies Keros Therapeutics Alternatives Tourmaline Bio Alternatives Altimmune Alternatives Zevra Therapeutics Alternatives Ginkgo Bioworks Alternatives Oruka Therapeutics Alternatives PureTech Health Alternatives Solid Biosciences Alternatives Monte Rosa Therapeutics Alternatives Erasca Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
